SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Herman Joseph)
 

Sökning: WFRF:(Herman Joseph) > Örebro universitet > Severe Spruelike En...

Severe Spruelike Enteropathy Associated With Olmesartan

Rubio-Tapia, Alberto (författare)
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN, United States
Herman, Margot L. (författare)
Department of Internal Medicine, Rochester MN, United States
Ludvigsson, Jonas F., 1969- (författare)
Karolinska Institutet
visa fler...
Kelly, Darlene G. (författare)
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States
Mangan, Thomas F. (författare)
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN, United States
Wu, Tsung-Teh (författare)
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN, United States
Murray, Joseph A. (författare)
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester MN, United States
visa färre...
 (creator_code:org_t)
Elsevier, 2012
2012
Engelska.
Ingår i: Mayo Clinic proceedings. - : Elsevier. - 0025-6196 .- 1942-5546. ; 87:8, s. 732-738
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objective: To report the response to discontinuation of olmesartan, an angiotensin II receptor antagonist commonly prescribed for treatment of hypertension, in patients with unexplained severe spruelike enteropathy.Patients and Methods: All 22 patients included in this report were seen at Mayo Clinic in Rochester, Minnesota, between August 1, 2008, and August 1, 2011, for evaluation of unexplained chronic diarrhea and enteropathy while taking olmesartan. Celiac disease was ruled out in all cases. To be included in the study, the patients also had to have clinical improvement after suspension of olmesartan.Results: The 22 patients (13 women) had a median age of 69.5 years (range, 47-81 years). Most patients were taking 40 mg/d of olmesartan (range, 10-40 mg/d). The clinical presentation was of chronic diarrhea and weight loss (median, 18 kg; range, 2.5-57 kg), which required hospitalization in 14 patients (64%). Intestinal biopsies showed both villous atrophy and variable degrees of mucosal inflammation in 15 patients, and marked subepithelial collagen deposition (collagenous sprue) in 7. Tissue transglutaminase antibodies were not detected. A gluten-free diet was not helpful. Collagenous or lymphocytic gastritis was documented in 7 patients, and microscopic colitis was documented in 5 patients. Clinical response, with a mean weight gain of 12.2 kg, was demonstrated in all cases. Histologic recovery or improvement of the duodenum after discontinuation of olmesartan was confirmed in all 18 patients who underwent follow-up biopsies.Conclusion: Olmesartan may be associated with a severe form of spruelike enteropathy. Clinical response and histologic recovery are expected after suspension of the drug. (C) 2012 Mayo Foundation for Medical Education and Research Mayo Clin Proc. 2012;87(8):732-738

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Allmänmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- General Practice (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy